Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) and Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.
Insider and Institutional Ownership
87.0% of Cartesian Therapeutics shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
Cartesian Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cartesian Therapeutics | $2.80 million | 70.98 | -$130.30 million | ($5.94) | -1.11 |
| Syndax Pharmaceuticals | $172.35 million | 7.17 | -$285.42 million | ($2.51) | -5.56 |
Cartesian Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Cartesian Therapeutics and Syndax Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cartesian Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Syndax Pharmaceuticals | 1 | 0 | 10 | 0 | 2.82 |
Cartesian Therapeutics currently has a consensus price target of $32.60, suggesting a potential upside of 396.19%. Syndax Pharmaceuticals has a consensus price target of $41.80, suggesting a potential upside of 199.64%. Given Cartesian Therapeutics’ higher possible upside, equities research analysts plainly believe Cartesian Therapeutics is more favorable than Syndax Pharmaceuticals.
Profitability
This table compares Cartesian Therapeutics and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cartesian Therapeutics | -8,550.65% | N/A | -29.84% |
| Syndax Pharmaceuticals | -87.52% | -372.94% | -39.11% |
Summary
Cartesian Therapeutics beats Syndax Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
